PRIMOVIST 🎖ïļ āļŠāļēāļĢāļ—āļķāļšāļĢāļąāļ‡āļŠāļĩ āđ€āļāļĄāļ­āļ­āļ™āđ„āļĨāļ™āđŒāđ€āļ‡āļīāļ™āļˆāļĢāļīāļ‡ 10 Ml āļˆāļģāļ™āļ§āļ™ 500

āđāļšāļĢāļ™āļ”āđŒ: PRIMOVIST

PRIMOVIST   PRIMOVIST 58105063666 āļŦāļ™āđˆāļ§āļĒāļ‡āļēāļ™āđ€āļˆāđ‰āļēāļ‚āļ­āļ‡āđ‚āļ„āļĢāļ‡āļāļēāļĢ āļ„āļ“āļ°āđāļžāļ—āļĒāļĻāļēāļŠāļ•āļĢāđŒ āđāļ™āļšāđ„āļŸāļĨāđŒāļ›āļĢāļ°āļāļēāļĻāļĢāļēāļ„āļēāļāļĨāļēāļ‡ cmurefprice 2015 1425859849 pdf on āļˆ, 10 26 2015 16 09 āļŠāļļāļĢāļīāļ™āļ—āļĢāđŒ āļˆāļąāļ™āļ—āļĢāđŒāļŠāļ°āļ­āļēāļ” āļˆāđˆāļēāļĒāļˆāļĢāļīāļ‡

PRIMOVIST āđ‚āļ”āļĒ m doyle · 2016 · āļ­āđ‰āļēāļ‡āđ‚āļ”āļĒ1 — aims to evaluate performance of mri with primovistÂŪ (bayer healthcare, germany) (pmri) in discriminating hepatic adenoma (ha) from focal nodular hyperplasia ( āļžāļ™āļąāļ™āļ­āļ­āļ™āđ„āļĨāļ™āđŒāļĄāļ·āļ­āļ–āļ·āļ­ primovist āđ‚āļ›āļĢāđ‚āļĄāļŠāļąāđˆāļ™āļŠāļĨāđ‡āļ­āļ• indications · evaluating focal nodular hyperplasia (fnh) vs adenoma hepatobiliary phase (20 minutes after contrast injection) · evaluation of hepatic āđ‚āļšāļ™āļąāļŠāļĢāļēāļĒāļ§āļąāļ™ primovist āļ—āļ”āļĨāļ­āļ‡āđ€āļĨāđˆāļ™āļŠāļĨāđ‡āļ­āļ•āļŸāļĢāļĩ

PRIMOVIST using a hepatobiliary contrast agent (e g eovist primovist, multihance) changes the evaluation of hepatic lesions five phases are often āđ€āļāļĄāļ„āļēāļŠāļīāđ‚āļ™āļ­āļ­āļ™āđ„āļĨāļ™āđŒ primovist āđāļ™āļ°āļ™āļģāđ€āļžāļ·āđˆāļ­āļ™āļĢāļąāļšāđ‚āļšāļ™āļąāļŠ āđ‚āļ”āļĒ sy yim · 2016 · āļ­āđ‰āļēāļ‡āđ‚āļ”āļĒ11 — meanwhile, gadoxetic acid enhanced mri is widely used to detect and characterize various hepatic nodules the high contrast generated by āļŠāļĨāđ‡āļ­āļ•āđāļ•āļāļŦāļ™āļąāļ primovist āđ€āļĨāđˆāļ™āļšāļ™āļĄāļ·āļ­āļ–āļ·āļ­

āļŋ5,940
āļŋ14,850 -60%
āļˆāļģāļ™āļ§āļ™
āļˆāļģāļŦāļ™āđˆāļēāļĒāđ‚āļ”āļĒ


Date Modified: 2024-10-11 02:41:24